AG真人官方

Sage Therapeutics, Inc. (SAGE) filed a Post-Effective Amendment to 15 outstanding Form S-8 registration statements.

The action follows the 31 July 2025 merger in which Supernus Pharmaceuticals acquired Sage through subsidiary Saphire, with Sage continuing as a wholly-owned subsidiary. Because all Sage equity offerings have ended, the company is deregistering every share that was registered but remains unissued or unsold. Affected registrations cover multiple plans, including 16.5 million shares under the 2024 Equity Incentive Plan as well as shares registered under the 2011 Stock Option & Grant Plan, 2014 Stock Option & Incentive Plan, 2014 ESPP and 2016 Inducement Equity Plan.

This filing is an administrative requirement under the Securities Act and carries no economic change to former Sage shareholders, whose consideration was fixed at merger close. It formally terminates Sage鈥檚 standalone equity plans, eliminates residual dilution risk, and contains no new financial results, guidance or liabilities.

AppFolio, Inc. (APPF) 鈥� Form 144 filing: A shareholder has filed notice to sell up to 30,000 common shares through Morgan Stanley Smith Barney on or about 1-Aug-2025 on Nasdaq. At the reported aggregate market value of $8.02 million, the implied price is roughly $267/share. The proposed sale equals only 鈮�0.13 % of the 22.87 million shares outstanding. The seller originally acquired the shares directly from the issuer on 12-Aug-2009 and reports no sales in the preceding three months.

Form 144 is a regulatory notice, not a definitive trade order, but it signals potential insider disposal under Rule 144. Given the small size relative to float and typical trading volumes, price impact should be minimal; nevertheless, investors may view any insider intent to sell as a mild negative sentiment indicator.

AppFolio, Inc. (APPF) 鈥� Form 144 filing: A shareholder has filed notice to sell up to 30,000 common shares through Morgan Stanley Smith Barney on or about 1-Aug-2025 on Nasdaq. At the reported aggregate market value of $8.02 million, the implied price is roughly $267/share. The proposed sale equals only 鈮�0.13 % of the 22.87 million shares outstanding. The seller originally acquired the shares directly from the issuer on 12-Aug-2009 and reports no sales in the preceding three months.

Form 144 is a regulatory notice, not a definitive trade order, but it signals potential insider disposal under Rule 144. Given the small size relative to float and typical trading volumes, price impact should be minimal; nevertheless, investors may view any insider intent to sell as a mild negative sentiment indicator.

Meta Platforms, Inc. (META) has filed a Form 144 indicating that insider Peggy Alford plans to sell 518 Class A common shares via Charles Schwab around 01 Aug 2025. The proposed sale is valued at $394,094, based on the market price stated in the notice. The shares originate from restricted-stock-unit (RSU) vesting events on 15 May 2023 (231 sh) and 15 May 2024 (287 sh).

With approximately 2.17 billion META shares outstanding, the transaction represents about 0.00002 % of the float, making its economic impact de-minimis. Alford previously sold 700 shares for $408,224 on 02 May 2025, bringing total disclosed insider dispositions in the past three months to 1,218 shares. Form 144 is a notice of intent; execution is not guaranteed and no operational or financial metrics are provided.

AppFolio, Inc. (APPF) filed a Form 144 indicating an insider鈥檚 intent to sell up to 3,000 Class A common shares, equal to roughly 0.013 % of the 22.87 million shares outstanding. The shares鈥攁cquired on 14-Feb-2007 as founder stock鈥攈ave an aggregate market value of about $802,140 based on the broker鈥檚 reference price. The proposed sale is expected to occur on or after 01-Aug-2025 through Morgan Stanley Smith Barney on Nasdaq. No other insider sales were reported for the past three months, and the filing contains no operational or financial updates.

Form 8-K (Item 2.02): On 31 Jul 2025 Shenandoah Telecommunications Company (NASDAQ: SHEN) furnished a press release and slide deck (Ex. 99.1) announcing its financial position as of 30 Jun 2025 and results for the three- and six-month periods then ended. The filing itself contains no revenue, earnings, margin or guidance figures; stakeholders must consult the exhibit or the Investor section of Shentel.com for quantitative details.

No other material events, transactions, leadership changes or capital actions are disclosed. Standard forward-looking-statement language is included. Because the information is 鈥渇urnished鈥� rather than 鈥渇iled,鈥� it is not subject to Section 18 liability. Exhibit 104 provides the Inline XBRL cover page tag set.

Independent Bank Corp. (IBCP) 鈥� Form 4 insider transaction

Director Ronia F. Kruse reported two acquisitions of phantom stock units under the company鈥檚 Deferred Compensation and Stock Purchase Plan for Non-Employee Directors:

• 15 May 2025: 172.90 units acquired at a reference price of $32.57.
• 01 Jul 2025: 685.66 units acquired at a reference price of $29.17.

After the transactions, Kruse鈥檚 total holdings in derivative phantom units rose to 22,517.77. These units are designed to mirror the value of IBCP common stock and will be settled in shares when the director retires from the Board.

No common shares were bought or sold on the open market, and the filing contains no indication of dispositions or sales. The transactions are routine, compensation-related awards that increase the director鈥檚 equity-linked exposure and further align board incentives with shareholder interests, but they do not change the public float or directly affect cash flow.

Forager Capital Management, LLC, together with its affiliated investment vehicle Forager Fund, L.P. and principals Edward Kissel and Robert MacArthur, has filed a Schedule 13G disclosing ownership of 2,186,472 shares of Viemed Healthcare, Inc. (VMD) common stock.

The position represents 5.5 % of Viemed鈥檚 39.52 million shares outstanding as reported in the company鈥檚 10-Q for the quarter ended 31 Mar 2025. Because the stake exceeds the 5 % threshold, the group is required to disclose its holdings under Section 13(d) of the Exchange Act. The filing is made pursuant to Rule 13d-1(b), indicating that the investors view the holding as passive rather than activist.

Voting and dispositive powers are split as follows: (i) Forager Fund and Forager Capital Management each hold sole voting and dispositive power over the full 2.19 million shares; (ii) Messrs. Kissel and MacArthur share voting and dispositive power over the same shares through their control of the fund and general partner. No other party is reported to have an economic interest in the shares.

The event date is 24 Jun 2025, with the joint filing signed on 1 Jul 2025. The certification clause confirms that the securities were not acquired with the intent to change or influence control of the issuer.

• The disclosure introduces a new institutional shareholder representing a sizeable block for a small-cap healthcare company.
• Filing type (Schedule 13G vs. 13D) suggests a passive, long-only orientation, reducing immediate governance or strategic pressure on Viemed.